Rajeev M. Shah
Sits on 25 boards. Overboarded · 25 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 25
- Current seats
- 25
- Board service
- 62 years
- Director since
- 2023
62 years of board service in total across 25 boards, counting each seat separately. Longest: Werewolf Therapeutics Inc., 3 years.
Werewolf Therapeutics Inc.
Director
Mineralys Therapeutics Inc.
Director
Black Diamond Therapeutics Inc.
Director
Climb Bio Inc.
Director
Tyra Biosciences Inc.
Director
Vor Biopharma Inc.
Director
Jade Biosciences Inc.
Director
Solid Biosciences Inc.
Director
Nkarta Inc.
Director
Acumen Pharmaceuticals Inc.
Director
Janux Therapeutics Inc.
Director
ARS Pharmaceuticals Inc.
Director
Wave Life Sciences Inc.
Director
PepGen Inc.
Director
LENZ Therapeutics Inc.
Director
Acrivon Therapeutics Inc.
Director
Artiva Biotherapeutics Inc.
Director
Bicara Therapeutics Inc.
Director
Septerna Inc.
Director
Sionna Therapeutics Inc.
Director
Evommune Inc.
Director
SpyGlass Pharma Inc.
Director
Hemab Therapeutics Holdings Inc.
Director
Parabilis Medicines Inc.
Director
Freenome Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 6, 2026 | Hemab Therapeutics Holdings Inc. | Open-market purchase | +14,611 | $23.77 | $347,303 |
| May 6, 2026 | Hemab Therapeutics Holdings Inc. | Open-market purchase | +53,407 | $24.83 | $1,326,096 |
| May 5, 2026 | Hemab Therapeutics Holdings Inc. | Open-market purchase | +87,143 | $24.59 | $2,142,846 |
| May 5, 2026 | Hemab Therapeutics Holdings Inc. | Open-market purchase | +10,268 | $25.00 | $256,700 |
| May 4, 2026 | Hemab Therapeutics Holdings Inc. | Derivative conversion | +3,607,846 | — | — |
| May 4, 2026 | Hemab Therapeutics Holdings Inc. | Derivative conversion | +1,009,052 | — | — |
| May 4, 2026 | Hemab Therapeutics Holdings Inc. | Derivative conversion | +221,188 | — | — |
| May 4, 2026 | Hemab Therapeutics Holdings Inc. | Open-market purchase | +2,541,250 | $18.00 | $45,742,500 |
| May 4, 2026 | Hemab Therapeutics Holdings Inc. | Open-market purchase | +133,750 | $18.00 | $2,407,500 |
| Apr 27, 2026 | Adicet Bio Inc. | Other | −250,000 | — | — |
| Apr 27, 2026 | Prelude Therapeutics Incorporated | Other | −1,407,000 | — | — |
| Apr 22, 2026 | Vor Biopharma Inc. | Open-market sale | −165,150 | $15.77 | $2,604,416 |
| Apr 10, 2026 | Vor Biopharma Inc. | Open-market sale | −828 | $15.75 | $13,041 |
| Apr 9, 2026 | Vor Biopharma Inc. | Open-market sale | −135,201 | $16.59 | $2,242,985 |
| Apr 8, 2026 | Vor Biopharma Inc. | Open-market sale | −353,242 | $16.32 | $5,764,909 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.